© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
474450 |
As an accredited 6-Bromo-1H-Indazol-3-Ylamine factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 6-Bromo-1H-Indazol-3-Ylamine prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Researchers and professionals involved in medicinal chemistry, agricultural sciences, or advanced materials find themselves continuously searching for new building blocks to fuel discovery. Among a rich palette of heterocyclic compounds, 6-Bromo-1H-Indazol-3-Ylamine steps into the spotlight, drawing attention for its unique structure and the flexibility it brings to complex molecule synthesis. This compound is more than a line on a chemical inventory list; it’s a versatile starting point for pathways leading to novel pharmaceuticals and advanced materials, thanks to its reactive amine group and strategic bromo substitution on the indazole core.
At first glance, 6-Bromo-1H-Indazol-3-Ylamine captures the imagination of experienced chemists because of the interplay between the indazole scaffold and the functional groups on the ring. The bromo atom at the 6-position creates an opportunity for cross-coupling reactions not easily achieved with unsubstituted indazoles. The amine at the 3-position invites a variety of nucleophilic attacks and modifications, paving the way for diverse derivatives. In my own work synthesizing kinase inhibitors, I have witnessed how specific ring substitutions can redefine biological activity. A subtle change, such as moving a bromo from the 5-position to the 6-position, may shift binding affinities, potentially unlocking new selectivities and improved pharmacokinetics.
Chemistry labs value substances that arrive exactly as represented. 6-Bromo-1H-Indazol-3-Ylamine commonly appears as a pale yellow to off-white solid, which helps to confirm both the identity and the absence of decomposition. Reliable suppliers offer this product with a typical purity above 98%—a crucial threshold in advanced synthesis, since even minor impurities can derail lengthy synthetic steps or produce ambiguous biological results. My experience handling indazole derivatives has shown that attention to purity pays off in improved reproducibility, less troubleshooting, and fewer unwelcome surprises in scale-up attempts.
In terms of solubility, this compound dissolves well in common polar aprotic solvents, like DMSO and DMF, which makes it straightforward to work into multi-step sequences. Having worked in both gram-scale research environments and larger pilot plants, I've seen quality differences among batches of similar compounds, often reflected in their melting point ranges and solubility. Those looking for scalable procedures appreciate materials that match published data and blend seamlessly into existing synthetic protocols.
In drug discovery, the indazole scaffold influences properties such as kinase selectivity and DNA binding. Medicinal chemists lean toward 6-Bromo-1H-Indazol-3-Ylamine for its utility in constructing indazole-based inhibitors targeting enzymes or receptors implicated in cancer and inflammation. The unique bromo and amine substituents provide handles for Suzuki, Buchwald–Hartwig, or nucleophilic aromatic substitution chemistries. These reactions open doors for rapid exploration of chemical space, something medicinal chemists crave when looking to optimize potency and selectivity.
Beyond the realm of pharmaceuticals, agricultural scientists exploring pesticides or herbicides have integrated indazole motifs to improve target specificity toward plant pathogens or insect enzymes. Materials chemists, always searching for new π-conjugated frameworks, include indazole derivatives in the development of molecules for organic electronics or fluorescent sensors. I’ve consulted with colleagues working in thin-film technologies, who have found the thermal stability of the indazole scaffold, paired with strategic bromo substitution, provides both processability and new optical properties for device applications.
The field for heterocyclic building blocks brims with choices, so every new entry faces questions of differentiation. The presence of the bromo group at position 6 distinguishes this compound from simpler analogues, like unsubstituted indazol-3-ylamine or indazoles with halogens elsewhere on the ring. The 6-position offers a precise entry point for palladium-catalyzed cross-coupling, a fact I’ve seen leveraged in the rapid generation of combinatorial libraries. Other indazole derivatives sometimes fall short in such uses because their substitutions limit regioselectivity or make purification a headache.
Another aspect that sets 6-Bromo-1H-Indazol-3-Ylamine apart from close cousins comes from the interplay between the electron-donating amine and the electron-withdrawing bromo. Adjusting such electronic influences on the core ring can make a world of difference. While some indazole amines are prone to oxidative degradation or polymerization, this species demonstrates enhanced stability and storage friendliness. This practical advantage resonates with those of us tired of opening a bottle only to find a darkened, useless lump of decomposition.
Compared with other heterocycles—like benzimidazoles, pyridines, or triazoles—indazoles bridge aromatic nitrogen heterocycles and fused systems, granting them a subtle blend of metabolic durability and binding novelty. I once ran comparative assays on a series of bromoindazoles, watching how minor relocation of the halogen atom converted selective inhibitors into broad-spectrum ones, or improved oral bioavailability by changing metabolic clearance rates. These real-world shifts underscore why precise substitutions like those on 6-Bromo-1H-Indazol-3-Ylamine matter far beyond the realm of catalog entries.
Scholarly papers and patents mirror the trend toward indazole derivatives in modern discovery. Published work by research teams in oncology and neurology illustrates how even a single atom change in an indazole ring alters protein binding, changing cellular outcomes. Computational chemists model electron density changes that ripple through substituted indazoles, explaining observed biological structure-activity relationships. If a tool molecule like 6-Bromo-1H-Indazol-3-Ylamine didn’t exist, medicinal chemists would need to synthesize it anyway—often at the cost of days lost to lengthy reaction schemes, with the additional risk of side products and low yields. Commercial availability at analytical-grade purity thus represents a boost in efficiency and reliability.
On the industry side, advances in process chemistry have further validated the practicality of this building block. Contract research organizations and pharmaceutical manufacturers frequently specify such intermediates in their kilo-lab and pilot plant development pipelines. In process development meetings, I’ve observed that stakeholders latch onto robust, high-yielding synthetic strategies. The presence of both a bromo and an amine reduces the step count to reach key drug intermediates, shrinking timelines and cost—critical metrics as drug programs transition from the lab to the clinic.
No chemical is without its challenges, and 6-Bromo-1H-Indazol-3-Ylamine poses some realities to practitioners. Secure sourcing from reputable suppliers ensures batch consistency and regulatory compliance, both necessities in industries facing significant scrutiny. Purchasing from subpar sources invites problems: off-target impurities, low yields, or unexpected reactivity can frustrate even the most patient lab teams. In my own purchasing experience, relying on partners with transparent supply chains relieves anxiety about origin and impurity profiles.
Handling this compound warrants respect for standard chemical hygiene. While not acutely toxic, derivatives of indazole can irritate upon contact or inhalation, especially if handled as aerosols or powders. Proper PPE, well-ventilated hoods, and the use of sealed containers protect both researcher and compound integrity. In long-term storage, keeping material cool, away from air and light, preserves freshness—a lesson reinforced after finding a precious custom batch partially oxidized after a summer in a warm, sunlit office.
Waste disposal, as always, should follow institutional protocols for halogenated aromatics. The bromo functionality makes this compound a candidate for further functionalization, but also demands respect for environmental impact when scaling up reactions or disposing of residues. From personal observation, labs that train for safe handling and routing of waste see lower incident rates and smoother audits.
Several recurring frustrations crop up with specialty heterocycles. Solubility challenges sometimes slow synthetic progress. When 6-Bromo-1H-Indazol-3-Ylamine lags behind expectations dissolving in less polar or nonpolar solvents, switching to DMSO or moderate heating often resolves the bottleneck. For reactions requiring anhydrous conditions, simple predrying over desiccants in a glove box keeps water-sensitive steps running efficiently.
On occasion, scale-up efforts encounter crystallization or batch-to-batch variability. Investing in high-quality, fully characterized starting materials mitigates this risk. In one memorable project, our team spent weeks troubleshooting an unexplained drop in reaction yield, only to trace the problem back to a batch produced using lower-grade precursors. After returning to a supplier with consistent product characterization, routine performance returned.
For researchers handling hazardous intermediates or byproducts, simple improvements such as local exhaust ventilation and clear procedural documentation shield both staff and projects from preventable accidents. Sharing best practices with incoming team members, paired with regular review of safety data, keeps a tight ship in any laboratory.
The landscape of discovery rarely stands still. As new targets emerge in oncology, infectious disease, and neuroscience, chemists tailor indazole derivatives to ever-more nuanced applications. Some emerging fields—such as covalent fragment screening, biologics conjugation, and photoaffinity labeling—continue to probe the boundaries of what indazole derivatives can do. The unique reactivity and substitution pattern of 6-Bromo-1H-Indazol-3-Ylamine invite creative adaptation into tool compounds, linkers, and functionalized small molecules.
Personal discussions with colleagues at academic and industry conferences consistently highlight indazole chemistry as a theme in modern bioactive molecule development. Even as computational methods expand, laboratory syntheses of diverse analogues still depend on reliable access to functionalized starting materials. Thus, the presence of bromo and amine functionalities on an indazole ring will likely continue shaping libraries for screening and development.
Having a broad toolkit of heterocycles suits the complexity of modern research, but selecting the right one often hinges on subtleties in reactivity or stability. While some labs default to simpler aniline or pyridine derivatives, the multifaceted reactivity of indazoles often lends a shortcut, saving time on protection-deprotection sequences or stepwise cross-couplings. The 6-bromo-3-amine pattern on indazole, in particular, offers a springboard for diversification.
Cost, availability, and safety also play roles in the decision-making process. In high-throughput screening, cost per gram and reliability of supply matter as much as synthetic flexibility. From my own purchasing experience, the ability to place a rush order for 6-Bromo-1H-Indazol-3-Ylamine, confident the delivered product will match the required purity, makes a big difference as grant and project deadlines approach.
Because the pharmaceutical sector runs parallel programs exploring several lead series in tandem, ease of modification at both the bromo and amine sites enables combinatorial exploration. This freedom supports structure-activity relationship studies, a staple of modern lead optimization.
As an early-stage intermediate, 6-Bromo-1H-Indazol-3-Ylamine rarely reaches the final formulation. Still, its impact ripples through the drug development lifecycle. Well-designed intermediates accelerate progress from initial screening to late-stage lead selection. The ability to reliably introduce varied aryl or heteroaryl substituents at the 6-position streamlines the progression from hit to candidate. Once a promising candidate emerges, downstream process chemists rely on scalable, reproducible access to the same core building blocks.
Working in interdisciplinary teams exposes the strengths—and the odd limitations—each chemical brings. Discovery scientists value fast-hit exploration, whereas development chemists care about scalability and robustness. The reliable chemistry of indazole bromo-amines, particularly at the 6-position, supports both camps, providing flexibility for early tinkering and stability in late-stage manufacture.
Despite the progress, the wish list from working medicinal chemists grows with each round of discovery. Some seek even higher-purity lots, or specialized isotopic labeling for tracing studies. Others champion the cause of expanded physical property data—solubility in more solvents, detailed NMR and mass spec spectra, or thermogravimetric analysis—for both safety and planning reasons. Over the years, I’ve appreciated suppliers who respond to these requests, cutting down on surprises and rework.
Ideally, every batch would include comprehensive certificate of analysis documents and transparent insight into residual solvent and contaminant data. In a regulatory environment increasingly focused on quality control and traceability, these documentations matter as much as the molecule itself. Open lines of communication between researchers and suppliers form the backbone of such progress.
One lasting lesson from my years in both academic and industrial settings comes from the value of open information sharing. The chemistry community has always thrived on feedback, collaboration, and honest reporting—not just of successes, but also failures and lessons learned. Feedback loops connecting suppliers, researchers, and developers accelerate both knowledge and practical improvements. With essential compounds like 6-Bromo-1H-Indazol-3-Ylamine, this community spirit shapes the path toward new medicines, advanced materials, and innovative tools for science.
For those starting with an idea sketched on a whiteboard and ending with a clinical candidate or a new material, the availability of trustworthy, high-quality intermediates makes the difference between clean, efficient progress and wasted cycles. From my vantage point, these considerations shape my own preference lists and influence the purchasing decisions I make, with an eye always focused not only on today's problems but on tomorrow's possibilities.
